Aβ immunization and anti-Aβ antibodies: Potential therapies for the prevention and treatment of Alzheimer's disease

Advanced Drug Delivery Reviews

Volumn 54, Issue 12, 2002, Pages 1603-1613

  Holtzman, David M ^a   Bales, Kelly R ^b   Paul, Steven M ^b   DeMattos, Ronald B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer's disease; Amyloid; Immunization; Transgenic mice

Indexed keywords

ANTIBODIES; BIOCHEMISTRY; BRAIN; DRUG THERAPY; NEUROLOGY;

GENETIC DATA;

IMMUNIZATION;

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; DRUG ANTIBODY; FREUND ADJUVANT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M266; PEPTIDE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY;

ACTIVE IMMUNIZATION; AGE; ALZHEIMER DISEASE; BETA SHEET; BIOCHEMISTRY; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; GENETICS; HUMAN; INFLAMMATION; NEUROPIL; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN MODIFICATION; REVIEW; SOLUBILITY; TOXICITY; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS; ANIMAL; IMMUNOLOGY; METHODOLOGY; MOUSE; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; HUMANS; IMMUNIZATION, PASSIVE; MICE; MICE, TRANSGENIC; VACCINATION;

EID: 0037038814     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00158-8     Document Type: Article

References (50)

1. Selkoe D.J. Alzheimer's disease: genotypes, phenotype, and treatments. Science. 275:1997;630-631.
2. Golde T.E., Eckman C.B., Younkin S.G. Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta. 1502:2000;172-187.
3. Price D.L., Sisodia S.S., Borchelt D.R. Genetic neurodegenerative diseases: the human illness and transgenic models. Science. 282:1998;1079-1083.
4. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
5. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
6. Borchelt D.R., Ratovitski T., Van Lare J., Lee M.K., Gonzales V.B., Jenkins N.A., Copeland N.G., Price D.L., Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice co-expressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19:1997;939-945.
7. Holcomb L.A., Gordon M.N., McGowan E., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Yu X., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.-M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. 4:1998;97-100.
8. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E., Little S., Cummins D., Piccardo P., Ghetti B., Black S.M. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nature Genet. 17:1997;263-264.
9. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97:2000;2892-2897.
10. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburb I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
11. Bard F., Cannon C., Barbour R., Burke R.-L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nature Med. 6:2000;916-919.
12. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.-C., Paul S.M., Holtzman D.M. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 98:2001;8850-8855.
13. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P., McConlogue L. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 94:1997;1550-1555.
14. Dodart J.C., Mathis C., Saura J., Bales K.R., Paul S.M., Ungerer A. Neuroanatomical abnormalities in behaviorally characterized APP(V717F) transgenic mice. Neurobiol. Dis. 7:2000;71-85.
15. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., Morris R.G. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408:2000;975-979.
16. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPsw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropath. Exp. Neurol. 56:1997;965-973.
17. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17:1997;7053-7059.
18. Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J. Neurosci. 16:1996;5795-5811.
19. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., Perry G. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70:1998;2212-2215.
20. Frautschy S.A., Yang F., Irizarry M., Hyman B., Saido T.C., Hsiao K., Cole G.M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 152:1998;307-317.
21. Jones M.W., Bliss T.V.P., Hsiao K.K., Chapman P.F. Age-dependent deficits in spatial memory and hippocampal LTP in vivo in APP transgenic mice. Soc. Neurosci. Abstr. 24:1998;729.
22. Hsia A.Y., Mucke L., Malenka R.C., Nicoll R.A. Overexpression of mutant β-amyloid precursor protein severely attenuates hippocampal synaptic transmission in an Alzheimer's disease mouse model. Soc. Neurosci. Abstr. 24:1998;729.
23. Le R., Cruz L., Urbanc B., Knowles R.B., Hsiao-Ashe K., Duff K., Irizarry M.C., Stanley H.E., Hyman B.T. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol. 60:2001;753-758.
24. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:2001;372-381.
25. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 95:1998;6448-6453.
26. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.-H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA. 94:1997;13287-13292.
27. Mucke L., Masliah E., Yu G.-Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20:2001;4050-4058.
28. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., StGeorge-Hyslop P., Westaway D. Aβ peptide immunization reduced behavioural impairment and plaques in a model of Alzheimer' s disease. Nature. 408:2000;979-982.
29. Lansbury P.T.J. Structural neurology: are seeds at the root of neuronal degeneration. Neuron. 19:1997;1151-1154.
30. Kowalewski T., Holtzman D.M. In situ AFM study of Alzheimer's β-amyloid peptide on different substrates: new insights into mechanism of β sheet formation. Proc. Natl. Acad. Sci USA. 96:1999;3688-3693.
31. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 19:1996;53-77.
32. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V., Ghetti B., Paul S.M. Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 96:1999;15233-15238.
33. Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., Bale K., Ashe K.H., Irizzary M.C., Hyman B.T. ApoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease. Ann. Neurol. 47:2000;739-747.
34. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Issazadeh S., Hancock W.W., Selkoe D.J. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48:2000;567-579.
35. Sigurdsson E.M., Scholtzova H., Mehta P., Frangione B., Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159:2001;439-447.
36. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Conner K., Hatcher J., Hope C., Gordon M., Arendash G.W. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
37. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Conner K., Hatcher J., Hope C., Gordon M., Arendash G.W. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease (correction). Nature. 412:2001;660.
38. Backsai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., Hyman B.T. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nature Med. 7:2001;369-372.
39. Backsai B.J., Kajdasz S.T., McLellen M.E., Games D., Seubert P., Schenk D., Hyman B.T. Multiple mechanisms are involved in clearance of amyloid-β by immunotherapy. Soc. Neurosci. Abstr. 27:2001;687.7.
40. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA. 94:1997;4109-4112.
41. Poduslo J.F., Curran G.L., Sanyal B., Selkoe D.J. Receptor-mediated transport of human amyloidβ protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol. Dis. 6:1999;190-199.
42. Poduslo J.F., Curran G.L. Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. NeuroReport. 12:2001;3197-3200.
43. Ghersi-Egea J.F., Gorevic P.D., Ghiso J., Frangione B., Patlak C.S., Fensternacher J.D. Fate of cerebrospinal fluid-borne amyloid β-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67:1996;880-883.
44. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Berislav B.L. Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:2000;1489-1499.
45. Ji Y., Permanne B., Sigurdsson E.M., Holtzman D.M., Wisniewski T. Amyloid β40/42 clearance across the blood-brain barrier following intraventricular injections in wild-type, apoE knockout and human apoE3 or E4 expressing transgenic mice. J. Alzheimer's Dis. 3:2001;23-30.
46. Lemere C.A., Spooner E.T., Malester B., LaFrancois J., Mori C., Leverone J.F., Clements J.T., Selkoe D.J., Duff K.E. Aβ immunization of PSAPP mice leads to decreased cerebral Aβ and a corresponding increase in serum Aβ Soc. Neurosci. Abstr. 27:2001;687.10.
47. Lee V.M.-Y. Aβ immunization: moving Aβ peptide from brain to blood. Proc. Natl. Acad. Sci. USA. 98:2001;8931-8932.
48. DeMattos R.B., Bales K.R., Parsadanian M., O'Dell M.A., Foss E.M., Paul S.M., Holtzman D.M. Plaque-associated disruption of CSF and plasma Aβ equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81:2002;229-236.
49. V717F transgenic mice. Soc. Neurosci. Abstr. 27:2001;687.12.
50. Peretz D., Williamson R.A., Kaneko K., Vergara J., Leclerc E., Mehlhorn I.R., Legname G., Wormald M.R., Rudd P.M., Burton D.R., Prusiner S.B. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature. 412:2001;739-743.